Drug companies do not simply invent medicines. They engineer legal structures designed to convert twenty years of patent protection into […]

The Counterintuitive Move That Makes Perfect Business Sense A brand pharmaceutical company holds an approved drug. No generic competitor has

A forensic comparison of the 505(b)(2) and 505(j) regulatory strategies that separate profitable pharmaceutical launches from expensive cautionary tales. The

A forensic guide to pharmaceutical life cycle extension: the IP strategies, regulatory mechanics, and commercial execution frameworks that separate drugs

Somewhere in the patent office’s public records, there is a graveyard. It has no physical address and no memorial plaques,

Pharmaceutical executives are losing control of their product narratives. While marketing teams focus on search engine optimization and field sales,

Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own

Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat

A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The